1ROWINSKY EK. Paclitaxel pharmacology, and other tumor types[J].Semin Oncol, 1997,24(6 Suppl 19) : 1-12.
2TREAT J,DAMJANOV N ,HUANG C.et al. Liposomal-encapsulated chemotherapy:preliminary, results of a phase I study of a novel liposomal paclitaxel [J] . Ontology, 2001,15 (5 Suppl 7 ) : 44-48.
3STRAUBINGER RM. ARNNOLD RD, ZHOU R. et al. Antivascular arid antitumor activities of liposome-associated drugs [J].Anticancer Res. 2004,24 (2A):397-404.
4CABANES A, BRIGGS KE, GOKHAI,E PC,et al. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel[J]. Int J Oncol, 1998,12(5 ) : 1035-1040.
5SHARMA A. MAYHEW E, BOEICSAK L. et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts[J]. Int J Cancer, 1997. 71( 1 ):103-107.
6Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21(17): 3194-3200.
7Vaseg PA, Atkinson R, Coleman R, et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer[J]. Br J Cancer, 2001, 84(2):170-178.
8Straubinger RM, Sharma A, MurrayM, et al. Novel taxol formulations: taxol-containing liposomes[J]. J Natl Cancer Inst Monogr, 1993, (15):69-78.
9Yang T, Cui FD, Choi MK, et al. Liposome formulation of paclitaxel with enhanced solubility and stability [J].Drug Deliv, 2007, 14(5):301-308.
